GT Medical Technologies Closes $53M Series D

By : Kyle Macdonald , COO of Silicon Oasis Arizona’s biotech scene continues to rise — and GT Medical Technologies , based in Tempe, just added major momentum with a $53 million Series D round , including a recent $16M extension. Founded by a team of neurosurgeons, radiation oncologists, and researchers from Barrow Neurological Institute, GT Medical is on a mission to improve the lives of brain tumor patients. Their flagship innovation, GammaTile® Therapy , is a small, implantable device that delivers targeted radiation directly to the site of tumor removal. It’sa breakthrough that allows patients to begin radiation immediately after surgery — helping reduce the risk of recurrence while protecting healthy brain tissue. This latest funding round will accelerate GT Medical’s commercial expansion, broaden hospital access, and support additional clinical studies. Already, over 1,900 patients have been treated with GammaTile at top institutions across the U.S. — and it all started here in Arizona. Meet the Founders: GT Medical was co-founded by: Dr . David Brachman (Radiation Oncologist, CTO) Dr . Peter Nakaji (Neurosurgeon) Dr . Heyoung McBride (Radiation Oncologist) Theresa Thomas (Clinical Research) and the late Dr . Emad Youssef — whose legacy lives on in the mission. This is more than a funding milestone — it’sa win for Arizona’s growing medtech ecosystem and a powerful example of what happens when clinical expertise meets entrepreneurial vision. 📬 Want more stories like this ?

Subscribe to the Silicon Oasis Magazine and stay up to date on Arizona’s most exciting founders, startups, and innovations.